Johnson and Johnson News

Shares of Johnson & Johnson have been in a solid uptrend throughout 2013. As shown in the chart below, the stock looks extended now, so investors should wait for a pullback.

In Part I of "Johnson & Johnson: At The Crossroads", it was determined that a dividend growth rate of 8.2% was sustainable for at least the next 15 years even if net income growth rate remained around the projected 6%. In Part II , it was determined that Johnson & Johnson had sufficient investable funds available at the end of 2012 to increase its ... (more)

Linked here is a detailed quantitative analysis of Johnson & Johnson . Below are some highlights from the above linked analysis: Company Description: Johnson & Johnson is a leader in the pharmaceutical, medical device and consumer products industries.

BIG PLANS: Johnson & Johnson says it's poised by 2017 to seek regulatory approval for a dozen new medicines and two dozen variations of existing ones.

Health-care giant Johnson & Johnson plans to seek approval for 10 new treatments to combat cancer, Hepatitis C, schizophrenia and influenza over the next four years, the company said Thursday.

Johnson & Johnson said its pharmaceutical unit plans to submit more than 10 new-product applications by 2017, as the health-care heavyweight hopes to build on the division's turnaround in recent years.

The firm set an "underperform" rating on the stock. A number of other firms have also recently commented on JNJ.

Johnson & Johnson says it plans to submit more than 10 new treatments to regulators for approval and 25 applications for additional uses of approved drugs by 2017.

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! In the wake of scandals and investigations over manufacturing gaffes, countless product recalls and questionable marketing practices, Johnson & Johnson is embarking on a round of corporate soul searching.

Bargains are getting harder and harder to find in the med-tech sector these days, and with Medtronic sporting a double-digit EV/EBITDA ratio and a 35% gain in the share price over the last year, it doesn't necessarily jump out as a bargain.

As JPMorgan Chase's annual shareholder meeting ended on Tuesday, the conveners played Bruce Hornsby's song " The Way It Is ." The celebratory DJ-ing came after shareholders voted down a proposal that would separate the role of the board's chairman from that of the CEO; Jamie Dimon currently fills both roles.

During the second half of the 20th century, there was a small handful of blue-chip stocks that served as a "secret handshake" of sorts among those steeped in dividend investing.

Hedge funds' returns have stayed "lackluster" this year, with the $2.3 trillion industry trailing the gains of the Standard & Poor's 500 Index by about 10 percentage points, according to Goldman Sachs Group Inc.

Meena is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.

Atlantic City's $2.4 billion Revel casino formally completed its financial restructuring and emerged from Chapter 11 bankruptcy Tuesday.

The firm is actively filing DePuy ASR lawsuits on behalf of those who allegedly suffered metallosis, premature device failure, or other serious complications related to the 2010 DePuy ASR recall.

A friend went into a kids hair salon and was asking about shampoo. The beautician said that there was a recent show on 20/20 or etc.

You will find a comprehensive dividend stock analysis of Johnson & Johnson in this article .

The single, easiest way to keep track of all the stocks that matter... Your own personalized stock watchlist! It's a 100% FREE Motley Fool service... The wealth-building power of compound interest will never cease to amaze me.

Though Janssen Korea says it is confident it will resolve its manufacturing issues, product recall and suspensions could be followed by lawsuits and imprisonment.